{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:55:51Z","timestamp":1777949751974,"version":"3.51.4"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>High-dose intravenous methylprednisolone (HD-IVMP) is the first-line treatment for dysthyroid optic neuropathy (DON). However, a significant proportion of patients exhibit a poor response, risking irreversible vision loss when surgical decompression is delayed. Identifying reliable predictors for failure of HD-IVMP is crucial for optimizing treatment strategies. This retrospective study aimed to identify risk factors associated with a poor response to HD-IVMP in DON patients, develop a predictive model for clinical decision-making, and assist in determining the optimal timing of orbital decompression surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study was conducted involving 44 patients (44 eyes) diagnosed with DON and treated with HD-IVMP. Basic characteristics, clinical features, orbital computed tomography (CT) findings, and laboratory parameters were analyzed. Treatment response was defined as complete visual recovery without requiring surgical decompression within 6\u202fmonths. Least absolute shrinkage and selection operator (LASSO) and multivariable logistic regression analyses were used to screen and identify independent predictive factors. The predictive performance of the model was evaluated by plotting the receiver operating characteristic (ROC) curve. Additionally, decision curve analysis (DCA), net reclassification index (NRI), integrated discrimination improvement (IDI), and bootstrap internal validation were used to evaluate the clinical utility of the model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At the 6-month follow-up, 20 of the 44 (42.5%) eyes achieved complete visual recovery and consequently avoided surgical decompression. A multivariable analysis identified three independent predictors of non-response to HD-IVMP: poorer baseline best-corrected visual acuity (BCVA; odds ratio [OR]\u202f=\u202f1.43, 95% CI: 1.05\u20131.95,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.04), higher thyroid-stimulating hormone receptor antibody (TRAb) levels (95% CI: 1.02\u20132.61, p\u202f=\u202f0.04), and elevated NLR (OR\u202f=\u202f1.30, 95% CI: 1.04\u20131.63,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.02). A combined predictive model integrating these factors demonstrated superior performance (AUC\u202f=\u202f0.944) with a sensitivity of 88% and a specificity of 85%, exceeding any single predictor. The internal validation also confirmed the model\u2019s robust clinical utility.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study establishes that baseline BCVA, TRAb, and NLR are significant and readily available risk factors for failure of HD-IVMP in DON. The developed combination model provides clinicians with a valuable tool for the early identification of patients who are unlikely to benefit from medical therapy alone, thereby facilitating timely surgical intervention to prevent permanent visual damage and improve overall management outcomes. External validation of this model is required in future prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1811285","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:24:54Z","timestamp":1777868694000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A combined model of BCVA, TRAb, and NLR predicts response to intravenous methylprednisolone in dysthyroid optic neuropathy"],"prefix":"10.3389","volume":"13","author":[{"given":"Shu","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Shanghai Changzheng Hospital, Second Affiliated Hospital of Naval Medical University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linfeng","family":"He","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shanghai Changzheng Hospital, Second Affiliated Hospital of Naval Medical University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruili","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shanghai Changzheng Hospital, Second Affiliated Hospital of Naval Medical University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/eje-21-0479","article-title":"The 2021 European group on graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of graves\u2019 orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41574-019-0305-4","article-title":"New insights into the pathogenesis and nonsurgical management of graves orbitopathy","volume":"16","author":"Taylor","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/s0002-9394(14)72787-4","article-title":"Diagnostic criteria for graves' Ophthalmopathy","volume":"119","author":"Bartley","year":"1995","journal-title":"Am J Ophthalmol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12886-020-1314-8","article-title":"Preoperative clinical factors and visual outcomes following orbital decompression with dysthyroid optic neuropathy","volume":"20","author":"Tagami","year":"2020","journal-title":"BMC Ophthalmol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s40618-023-02036-0","article-title":"Dysthyroid optic neuropathy: emerging treatment strategies","volume":"46","author":"Pelewicz-Sowa","year":"2023","journal-title":"J Endocrinol Investig"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40618-020-01361-y","article-title":"Dysthyroid optic neuropathy: evaluation and management","volume":"44","author":"Dolman","year":"2020","journal-title":"J Endocrinol Investig"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1089\/thy.2013.0445","article-title":"Therapeutic outcomes of high-dose intravenous steroids in the treatment of Dysthyroid optic neuropathy","volume":"24","author":"Curr\u00f2","year":"2014","journal-title":"Thyroid"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/s0161-6420(89)32784-9","article-title":"Methylprednisolone pulse therapy in severe Dysthyroid optic neuropathy","volume":"96","author":"Guy","year":"1989","journal-title":"Ophthalmology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1097\/iop.0000000000001146","article-title":"Dysthyroid optic neuropathy","volume":"34","author":"Saeed","year":"2018","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1153312","DOI":"10.3389\/fendo.2023.1153312","article-title":"Prognostic significance of thyroid-stimulating hormone receptor antibodies in moderate-to-severe graves\u2019 orbitopathy","volume":"14","author":"Park","year":"2023","journal-title":"Front Endocrinol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12886-023-02789-5","article-title":"A single-center analysis of visual outcomes and associated factors after intravenous methylprednisolone treatment for dysthyroid optic neuropathy","volume":"23","author":"Kemchoknatee","year":"2023","journal-title":"BMC Ophthalmol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1136\/bjo.2006.110932","article-title":"Dysthyroid optic neuropathy: a clinical diagnosis or a definable entity?","volume":"91","author":"Dayan","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/00002341-200205000-00005","article-title":"CT scan evidence of Dysthyroid optic neuropathy","volume":"18","author":"Giaconi","year":"2002","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3341\/kjo.2012.26.2.73","article-title":"Clinical profile and visual outcomes after treatment in patients with Dysthyroid optic neuropathy","volume":"26","author":"Jeon","year":"2012","journal-title":"Korean J Ophthalmol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/bjo.73.8.639","article-title":"Clinical criteria for the assessment of disease activity in graves' ophthalmopathy: a novel approach","volume":"73","author":"Mourits","year":"1989","journal-title":"Br J Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1136\/bjo.2006.094607","article-title":"Clinical features of dysthyroid optic neuropathy: a European group on graves' Orbitopathy (EUGOGO) survey","volume":"91","author":"McKeag","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"722","DOI":"10.4149\/bll_2015_142","article-title":"Neutrophil-to-lymphocyte ratio is involved in the severity of ankylosing spondylitis","volume":"116","author":"Kucuk","year":"2015","journal-title":"Bratislava Medical J"},{"key":"ref18","first-page":"593","article-title":"Is there a link between neutrophil-lymphocyte ratio and microvascular complications in geriatric diabetic patients?","volume-title":"J Endocrinol Invest","author":"\u00d6zt\u00fcrk","year":"2013"},{"key":"ref19","first-page":"358","article-title":"Role of neutrophil\/lymphocyte ratio in prediction of disease progression in patients with stage-4 chronic kidney disease","volume-title":"J. Nephrol.","author":"Ismail","year":"2012"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.3390\/jcm9103111","article-title":"Neutrophil-to-lymphocyte, monocyte-to-lymphocyte and platelet-to-lymphocyte ratios in relation to clinical parameters and smoking status in patients with graves' Orbitopathy-novel insight into old tests","volume":"9","author":"Joanna","year":"2020","journal-title":"J Clin Med"},{"key":"ref21","first-page":"495","article-title":"Neutrophil-to-lymphocyte ratio in thyroid ophthalmopathy","volume-title":"Bratisl Lek Listy.","author":"Celik","year":"2017"},{"key":"ref22","first-page":"406","article-title":"High neutrophil-to-lymphocyte ratio is associated with relapse in graves' disease after antithyroid drug therapy","volume-title":"Endocr.","author":"Mijin","year":"2019"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1177\/10507256251372194","article-title":"Teprotumumab treatment in patients with steroid and surgery-resistant dysthyroid optic neuropathy: a case series","volume":"35","author":"Carretti","year":"2025","journal-title":"Thyroid"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1556742","DOI":"10.3389\/fimmu.2025.1556742","article-title":"Key indicators for guiding tocilizumab therapy to prevent orbital decompression surgery in hormone-resistant dysthyroid optic neuropathy","volume":"16","author":"Shu","year":"2025","journal-title":"Front Immunol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.18240\/ijo.2019.11.12","article-title":"The effect of intravenous high-dose glucocorticoids and orbital decompression surgery on sight-threatening thyroid-associated ophthalmopathy","volume":"12","author":"Wen","year":"2019","journal-title":"Int J Ophthalmol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/9323450","article-title":"The therapeutic effect of combination of orbital decompression surgery and methylprednisolone pulse therapy on patients with bilateral dysthyroid optic neuropathy","volume":"2020","author":"Xu","year":"2020","journal-title":"J Ophthalmol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2265.2005.02345.x","article-title":"Surgical or medical decompression as a first-line treatment of optic neuropathy in graves\u2019 ophthalmopathy? A randomized controlled trial","volume":"63","author":"Wakelkamp","year":"2005","journal-title":"Clin Endocrinol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1076\/orbi.20.4.275.2612","article-title":"Methylprednisolone pulse therapy for patients with dysthyroid optic neuropathy","volume":"20","author":"Mourits","year":"2001","journal-title":"Orbit (Amsterdam)"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1089\/jop.2005.21.328","article-title":"Early response to intravenous glucocorticoids for severe thyroid-associated ophthalmopathy predicts treatment outcome","volume":"21","author":"Hart","year":"2005","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"166","DOI":"10.5603\/EP.a2016.0018","article-title":"Powr\u00f3t pe\u0142nej ostro\u015bci wzroku jako g\u0142\u00f3wny cel leczenia pacjent\u00f3w z neuropati\u0105 nerwu wzrokowego w przebiegu orbitopatii Gravesa","volume":"67","author":"Mi\u015bkiewicz","year":"2016","journal-title":"Endokrynol Pol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1038\/s41433-020-0897-x","article-title":"Evaluation of medical and surgical decompression in patients with dysthyroid optic neuropathy","volume":"34","author":"Garip","year":"2020","journal-title":"Eye"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1136\/bjo.2004.050807","article-title":"Quantification of cells expressing the thyrotropin receptor in extraocular muscles in thyroid associated orbitopathy","volume":"89","author":"Boschi","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s40618-020-01353-y","article-title":"Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of graves\u2019 orbitopathy","volume":"44","author":"Nicol\u00ec","year":"2020","journal-title":"J Endocrinol Investig"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s40618-020-01380-9","article-title":"Thyrotropin receptor antibodies and graves\u2019 orbitopathy","volume":"44","author":"Diana","year":"2020","journal-title":"J Endocrinol Investig"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/joim.13524","article-title":"Current concepts regarding graves\u2019 orbitopathy","volume":"292","author":"Bartalena","year":"2022","journal-title":"J Intern Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1546211","DOI":"10.3389\/fendo.2025.1546211","article-title":"Combining biomarkers to predict the disease activity of graves\u2019 ophthalmopathy: a combinatory model of the NLR, TRAb and FT4","volume":"16","author":"Niu","year":"2025","journal-title":"Front Endocrinol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"105054","DOI":"10.1016\/j.idnow.2025.105054","article-title":"The neutrophil-to-lymphocyte ratio in bronchoalveolar lavage fluid could help to personalize corticosteroid therapy in severe COVID-19 pneumonia","volume":"55","author":"Beaudequin","year":"2025","journal-title":"Infectious Diseases Now"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1811285\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:24:55Z","timestamp":1777868695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1811285\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":37,"alternative-id":["10.3389\/fmed.2026.1811285"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1811285","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"article-number":"1811285"}}